16:08 EDT Bicycle Therapeutics (BCYC) files $500M mixed securities shelf
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics: Strategic Cost Reduction and Program Advancements Justify Buy Rating
- Bicycle Therapeutics Appoints Charles Swanton to Board
- Bicycle Therapeutics reports Q2 EPS ($1.14), consensus (93c)
- Bicycle Therapeutics price target lowered to $25 from $32 at RBC Capital
- Bicycle Therapeutics Approves Proposals at Annual Meeting